Logo image of SWTX

SPRINGWORKS THERAPEUTICS INC (SWTX) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:SWTX - US85205L1070 - Common Stock

46.99 USD
+0.01 (+0.02%)
Last: 6/30/2025, 8:00:01 PM
46.98 USD
-0.01 (-0.02%)
After Hours: 6/30/2025, 8:00:01 PM
Fundamental Rating

4

SWTX gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 529 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for SWTX as it has an excellent financial health rating, but there are worries on the profitability. SWTX is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

In the past year SWTX has reported negative net income.
In the past year SWTX has reported a negative cash flow from operations.
SWTX had negative earnings in each of the past 5 years.
SWTX had a negative operating cash flow in each of the past 5 years.
SWTX Yearly Net Income VS EBIT VS OCF VS FCFSWTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M

1.2 Ratios

SWTX has a Return On Assets (-50.25%) which is comparable to the rest of the industry.
Looking at the Return On Equity, with a value of -60.84%, SWTX is in the better half of the industry, outperforming 60.14% of the companies in the same industry.
Industry RankSector Rank
ROA -50.25%
ROE -60.84%
ROIC N/A
ROA(3y)-44.26%
ROA(5y)-35.82%
ROE(3y)-51.76%
ROE(5y)-40.92%
ROIC(3y)N/A
ROIC(5y)N/A
SWTX Yearly ROA, ROE, ROICSWTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -10 -20 -30 -40 -50

1.3 Margins

SWTX has a Gross Margin of 93.23%. This is amongst the best in the industry. SWTX outperforms 94.31% of its industry peers.
The Profit Margin and Operating Margin are not available for SWTX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 93.23%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SWTX Yearly Profit, Operating, Gross MarginsSWTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K

More info and screens

7

2. Health

2.1 Basic Checks

SWTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
SWTX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, SWTX has more shares outstanding
There is no outstanding debt for SWTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
SWTX Yearly Shares OutstandingSWTX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
SWTX Yearly Total Debt VS Total AssetsSWTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

SWTX has an Altman-Z score of 20.07. This indicates that SWTX is financially healthy and has little risk of bankruptcy at the moment.
SWTX's Altman-Z score of 20.07 is amongst the best of the industry. SWTX outperforms 93.59% of its industry peers.
SWTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 20.07
ROIC/WACCN/A
WACC9.79%
SWTX Yearly LT Debt VS Equity VS FCFSWTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M

2.3 Liquidity

SWTX has a Current Ratio of 4.33. This indicates that SWTX is financially healthy and has no problem in meeting its short term obligations.
SWTX has a Current ratio (4.33) which is comparable to the rest of the industry.
SWTX has a Quick Ratio of 4.18. This indicates that SWTX is financially healthy and has no problem in meeting its short term obligations.
SWTX has a Quick ratio (4.18) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.33
Quick Ratio 4.18
SWTX Yearly Current Assets VS Current LiabilitesSWTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 33.79% over the past year.
The Revenue has grown by 730.42% in the past year. This is a very strong growth!
EPS 1Y (TTM)33.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.93%
Revenue 1Y (TTM)730.42%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%133.68%

3.2 Future

The Earnings Per Share is expected to grow by 19.73% on average over the next years. This is quite good.
SWTX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 40.44% yearly.
EPS Next Y19.4%
EPS Next 2Y25.17%
EPS Next 3Y32.89%
EPS Next 5Y19.73%
Revenue Next Year71.54%
Revenue Next 2Y73.57%
Revenue Next 3Y60.55%
Revenue Next 5Y40.44%

3.3 Evolution

SWTX Yearly Revenue VS EstimatesSWTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
SWTX Yearly EPS VS EstimatesSWTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 -4

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

SWTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SWTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SWTX Price Earnings VS Forward Price EarningsSWTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SWTX Per share dataSWTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

SWTX's earnings are expected to grow with 32.89% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.17%
EPS Next 3Y32.89%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SWTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SPRINGWORKS THERAPEUTICS INC

NASDAQ:SWTX (6/30/2025, 8:00:01 PM)

After market: 46.98 -0.01 (-0.02%)

46.99

+0.01 (+0.02%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-09 2025-05-09/amc
Earnings (Next)08-05 2025-08-05/bmo
Inst Owners85.23%
Inst Owner Change-99.32%
Ins Owners1.38%
Ins Owner Change-31.24%
Market Cap3.54B
Revenue(TTM)219.67M
Net Income(TTM)-253.93M
Analysts50.91
Price Target53.33 (13.49%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-40.05%
Min EPS beat(2)-44.63%
Max EPS beat(2)-35.47%
EPS beat(4)2
Avg EPS beat(4)-5.34%
Min EPS beat(4)-44.63%
Max EPS beat(4)52.52%
EPS beat(8)5
Avg EPS beat(8)-3.18%
EPS beat(12)7
Avg EPS beat(12)-2.43%
EPS beat(16)7
Avg EPS beat(16)-7.99%
Revenue beat(2)1
Avg Revenue beat(2)-12.64%
Min Revenue beat(2)-27.36%
Max Revenue beat(2)2.07%
Revenue beat(4)2
Avg Revenue beat(4)9.03%
Min Revenue beat(4)-27.36%
Max Revenue beat(4)70.52%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-28.25%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-12.25%
EPS NY rev (1m)-7.21%
EPS NY rev (3m)-15.2%
Revenue NQ rev (1m)-3.51%
Revenue NQ rev (3m)-4.74%
Revenue NY rev (1m)-2.75%
Revenue NY rev (3m)-6.25%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 16.11
P/FCF N/A
P/OCF N/A
P/B 8.48
P/tB 8.48
EV/EBITDA N/A
EPS(TTM)-3.41
EYN/A
EPS(NY)-1.51
Fwd EYN/A
FCF(TTM)-2.46
FCFYN/A
OCF(TTM)-2.2
OCFYN/A
SpS2.92
BVpS5.54
TBVpS5.54
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -50.25%
ROE -60.84%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 93.23%
FCFM N/A
ROA(3y)-44.26%
ROA(5y)-35.82%
ROE(3y)-51.76%
ROE(5y)-40.92%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.43
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 524.84%
Cap/Sales 9.17%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.33
Quick Ratio 4.18
Altman-Z 20.07
F-Score6
WACC9.79%
ROIC/WACCN/A
Cap/Depr(3y)788.2%
Cap/Depr(5y)591.94%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)33.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.93%
EPS Next Y19.4%
EPS Next 2Y25.17%
EPS Next 3Y32.89%
EPS Next 5Y19.73%
Revenue 1Y (TTM)730.42%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%133.68%
Revenue Next Year71.54%
Revenue Next 2Y73.57%
Revenue Next 3Y60.55%
Revenue Next 5Y40.44%
EBIT growth 1Y26.31%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year30.32%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-0.05%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y5.3%
OCF growth 3YN/A
OCF growth 5YN/A

SPRINGWORKS THERAPEUTICS INC / SWTX FAQ

Can you provide the ChartMill fundamental rating for SPRINGWORKS THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 3 / 10 to SWTX.


Can you provide the valuation status for SPRINGWORKS THERAPEUTICS INC?

ChartMill assigns a valuation rating of 1 / 10 to SPRINGWORKS THERAPEUTICS INC (SWTX). This can be considered as Overvalued.


Can you provide the profitability details for SPRINGWORKS THERAPEUTICS INC?

SPRINGWORKS THERAPEUTICS INC (SWTX) has a profitability rating of 1 / 10.